ETR:BIO - Biotest Stock Price, News, & Analysis

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Cytotect for cytomegalovirus infections; and Fovepta for hepatitis B prophylaxis in newborns. The company's products also comprise Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; and Pentaglobin to treat bacterial infections. The company's products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat cytomegalovirus infections; Trimodulin for the community-acquired pneumonia; and Fibrinogen to treat fibrinogen deficiency. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. As of January 19, 2018, Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng International Investment Limited.

Biotest (ETR:BIO) Frequently Asked Questions

What is Biotest's stock symbol?

Biotest trades on the ETR under the ticker symbol "BIO."

What price target have analysts set for BIO?

1 brokers have issued 12 month price objectives for Biotest's shares. Their forecasts range from €24.10 to €24.10. On average, they expect Biotest's stock price to reach €24.10 in the next year. This suggests a possible upside of 0.8% from the stock's current price. View Analyst Price Targets for Biotest.

What is the consensus analysts' recommendation for Biotest?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biotest in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biotest.

Has Biotest been receiving favorable news coverage?

News stories about BIO stock have trended very positive on Tuesday, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Biotest earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are some of Biotest's key competitors?

Some companies that are related to Biotest include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).

Who are Biotest's key executives?

Biotest's management team includes the folowing people:

• Dr. Bernhard R. M. Ehmer, Chairman of Management & CEO (Age 63)
• Dr. Michael Ramroth, CFO, Head of Fin.s & Central Services and Member of the Board of Management
• Dr. Georg Floß, COO & Member of the Board of Management
• Dr. Monika Buttkereit, Head of Investor Relations
• Dr. Katrin Bernöster, Head of the Project Management Organisation

What is Biotest's stock price today?

One share of BIO stock can currently be purchased for approximately €23.90.

What is Biotest's official website?

The official website for Biotest is http://www.biotest.com/de/.

How can I contact Biotest?

Biotest's mailing address is Landsteinerstr. 5, DREIEICH, 63303, Germany. The company can be reached via phone at +49-6103-8010.